Advertisement

Advertisement

Medical Literature

Sintilimab Plus Pemetrexed and Platinum for NSCLC: Updated ORIENT-11 Study Results

Medical Literature

Real-World View From Germany: Bevacizumab-Containing Therapy for Locally or Metastatic Breast Cancer

News

SITC 2021: How Genetic Reprogramming of Merkel Cell Carcinoma May Impact MHC-I Expression and Immune Response

News

SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC

Medical Literature

Is T-DXd Active Against <em>HER2</em>-Mutant NSCLC?

News

Can Inflammation Score Predict Effect of Tislelizumab in Squamous NSCLC?

News

Pembrolizumab Approved by FDA for Adjuvant Treatment of Renal Cell Carcinoma

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Cristina Saura, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

View More

Advertisement

JNCCN Spotlights

Elotuzumab

(UPDATE) Daratumumab (MM)

UPDATE Nivolumab and Ipilimumab in Renal Cell Carcinoma

(UPDATE) Pembrolizumab (NSCLC)

View More

More

News

SITC 2021: Preclinical Study of Microbial Immunotherapy in Bladder Cancer

Lenalidomide Maintenance Therapy for Multiple Myeloma: Is Longer Better?

Front-Line Daratumumab Triplet: Updated Overall Survival Results From MAIA

Can Prior Nephrectomy Improve Outcomes With Immunotherapy for Metastatic Kidney Cancer?

Pediatric <em>KMT2A</em>-Rearranged AML: CD33-Targeted Agent Focus of Phase III Trial

SITC 2021: Anti-CD47 Immunotherapy Under Study for Reducing Breast Cancer Brain Metastasis

Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes

Sintilimab Plus Pemetrexed and Platinum for NSCLC: Updated ORIENT-11 Study Results

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy

JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.